Jnana Therapeutics Inc. has described sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of diabetes, chronic kidney disease, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), phenylketonuria, metabolic syndrome, obesity, neurodevelopmental disorders and autism spectrum disorders, among others.
Xenon Pharmaceuticals Inc. has divulged potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators reported to be useful for the treatment of pain, anhedonia, depression and seizure disorders.
Raythera Inc. has identified TNF-α modulators reported to be useful for the treatment of inflammatory disorders, autoimmune disease, neurological disorders, pain, cardiovascular disorders, cancer, metabolic disorders and eye disorders.
Virginia Commonwealth University has synthesized nitrogen-walk derivatives of NAN acting as µ-opioid receptor modulators reported to be useful for the treatment of pain, opioid dependency and neurological disorders.
Taichengsi (Shanghai) Biomedical Co. Ltd. has described antibody-drug conjugates comprising an antibody covalently bound to a cytotoxic drug through a bivalent olefin linker optionally consisting of an isotope-labeled compound reported to be useful for the treatment of cancer.
Shenzhen Hightide Biotechnology Ltd. has divulged prodrugs and derivatives of 2,4-dinitro phenol reported to be useful for the treatment of obesity, diabetes, liver disease, heart disease, renal failure, neurodegenerative diseases and aging, among others.
Scientists at Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have synthesized protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Mindrank Therapeutics (Suzhou) New Drug Research & Development Co. Ltd. has disclosed cellular tumor antigen p53 (TP53) (Y220C mutant) stabilizers reported to be useful for the treatment of cancer.
RSS